Compound News and Research

RSS

Small molecules may inhibit entry of Ebola into human cells

Ebola, a virus that causes deadly hemorrhagic fever in humans, has no known cure or vaccine. But a new study by University of Illinois at Chicago scientists has uncovered a family of small molecules which appear to bind to the virus's outer protein coat and may inhibit its entry into human cells.

20 Jan 2011

Dextran-coated onto iron oxide nanoparticles can detect cholera toxin: Study

A complex sugar may someday become one of the most effective weapons to stop the spread of cholera, a disease that has claimed thousands of lives in Haiti since the devastating earthquake last year.

19 Jan 2011

Researchers create biyouyanagin compound library

Using chemical compounds found in a Japanese plant as a lead and the clever application of ultraviolet light, a Scripps Research Institute team has created a unique library of dozens of synthetic compounds to test for biomedical potential. Already, one of the compounds has shown great promise in inhibiting replication of HIV particles and fighting inflammation.

19 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer.

19 Jan 2011

FDA approves ParaPRO's Natroba for topical treatment of head lice

ParaPRO, LLC announced today that the U.S. Food and Drug Administration has approved Natroba Topical Suspension, 0.9% to eliminate head lice. Natroba received approval as a prescription medication and is indicated for the topical treatment of head lice infestations in patients four years of age and older.

18 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Harbor BioSciences, Inc., a leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals, announced it has licensed the research and development and commercialization rights for three of its products, exclusively in the People's Republic of China and Hong Kong, to China State Institute of Pharmaceutical Industry (CIPI).

18 Jan 2011

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Seordus recieves Japanese patent for SER100

The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

18 Jan 2011

US market for orthopedic extremity devices to grow at 10% CAGR to $4.6 billion by 2015

According to Millennium Research Group, the global authority on medical technology market intelligence, the prosperity of the US market for orthopedic extremity devices will be bolstered by continued product innovation and surgeon specialization. Despite sluggish economic performance in the US market and impending regulatory changes imposed by health care reform, the US orthopedic extremity device market will generate over $4.6 billion in revenues by 2015, growing at a compound annual growth rate in excess of 10%.

18 Jan 2011

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

13 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

BPA more harmful to women with hormonal and fertility imbalances

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), found higher Bisphenol A (BPA) levels in women with polycystic ovary syndrome (PCOS) compared to controls. Furthermore, researchers found a statistically significant positive association between male sex hormones and BPA in these women suggesting a potential role of BPA in ovarian dysfunction.

13 Jan 2011

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

The Scripps Research Institute and the University of Pennsylvania School of Medicine have been awarded approximately $8.2 million over five years to develop novel compounds that could eventually become drug candidates for the treatment of tobacco addiction. Of the funds awarded, $5.7 million will go to Scripps Research, and $2.5 million to the University of Pennsylvania.

12 Jan 2011

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

AstraZeneca and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

12 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Resveratrol stimulates expression of adiponectin hormone: Study

Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects.

10 Jan 2011

Compound News and Research

Small molecules may inhibit entry of Ebola into human cells

Dextran-coated onto iron oxide nanoparticles can detect cholera toxin: Study

Researchers create biyouyanagin compound library

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

FDA approves ParaPRO's Natroba for topical treatment of head lice

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Seordus recieves Japanese patent for SER100

US market for orthopedic extremity devices to grow at 10% CAGR to $4.6 billion by 2015

TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

BPA more harmful to women with hormonal and fertility imbalances

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Resveratrol stimulates expression of adiponectin hormone: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News